ZTZelin Tian

Zelin Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zelin Tian has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP

    by Zelin Tian, Chen Xu, Weixiang He, Zhibin Lin, Wenjie Zhang, Kaishan Tao, Rui Ding, Xuan Zhang, Kefeng Dou


  • Open Access

    Identification of a 9‐gene prognostic signature for breast cancer

    by Zelin Tian, Jianing Tang, Xing Liao, Qian Yang, Yumin Wu, Gaosong Wu

    Breast cancer (BRCA) is the most common cancer among women and is the second leading cause of cancer death in women. In this study, we developed a 9‐gene prognostic signature to predict the prognosis of patients with BRCA. GSE20685, GSE42568, GSE20711, and GSE88770 were used as training sets. The Kaplan–Meier plot was constructed to assess survival differences and log‐rank test was performed to evaluate the statistical significance. The overall survival (OS) of patients in the low‐risk group was significantly higher than that in the high‐risk group. ROC analysis indicated that this 9‐gene signature shows good diagnostic efficiency both in OS and disease‐free survival (DFS). The 9‐gene signature was further validated through GSE16446, GSE7390, and TCGA‐BRCA datasets. We also established a nomogram that integrates clinicopathological features and 9‐gene signature. The analysis of the calibration plot showed that the nomogram has good prognostic performance. More convincingly, real‐time reverse transcription‐polymerase chain reaction (RT‐PCR) results indicated that the protective prognostic factors in BRCA patients were downregulated, whereas the dangerous prognostic factors were upregulated. The innovation of this article is not only constructing a prognostic gene signature, but also combining with clinical information to further establish a nomogram to better predict the survival probability of patients. It is worth mentioning that this signature also does not depend on other clinical factors or variables.


  • Open Access

    An immune‐related prognostic signature for predicting breast cancer recurrence

    by Zelin Tian, Jianing Tang, Xing Liao, Qian Yang, Yumin Wu, Gaosong Wu

    Breast cancer (BC) is the most common cancer among women worldwide and is the second leading cause of cancer‐related deaths in women. Increasing evidence has validated the vital role of the immune system in BC development and recurrence. In this study, we identified an immune‐related prognostic signature of BRCA that could help delineate risk scores of poor outcome for each patient. This prognostic signature comprised information on five danger genes—TSLP, BIRC5, S100B, MDK, and S100P—and three protect genes RARRES3, BLNK, and ACO1. Kaplan‐Meier survival curve showed that patients classified as low‐risk according to optimum cut‐off risk score had better prognosis than those identified within the high‐risk group. ROC analysis indicated that the identified prognostic signature had excellent diagnostic efficiency for predicting 3‐ and 5‐years relapse‐free survival (RFS). Multivariate Cox regression analysis proved that the prognostic signature is independent of other clinical parameters. Stratification analysis demonstrated that the prognostic signature can be used to predict the RFS of BC patients within the same clinical subgroup. We also developed a nomogram to predict the RFS of patients. The calibration plots exhibited outstanding performance. The validation sets (GSE21653, GSE20711, and GSE88770) were used to external validation. More convincingly, the real time RT‐PCR results of clinical samples demonstrated that danger genes were significantly upregulated in BC samples, whereas protect genes were downregulated. In conclusion, we developed and validated an immune‐related prognostic signature, which exhibited excellent diagnostic efficiency in predicting the recurrence of BC, and will help to make personalized treatment decisions for patients at different risk score.


  • Open Access

    Identification of a 9-Gene Prognostic signature for breast cancer

    by Zelin Tian, Jianing Tang, Xing Liao, Qian Yang, Yumin Wu, Gaosong Wu

    Background Breast cancer (BRCA) is the most common cancer among women worldwide and results in the second leading cause of woman cancer death.Methods This study sought to develop a prognostic gene signature to predict the prognosis of patients with BRCA. Studies were performed using the genome-wide data of BRCA patients from the Gene Expression Omnibus dataset (GSE20685, GSE42568, GSE20711, GSE88770). Univariate COX regression analysis was used to determine the association between gene expression levels and overall survival(OS) in each dataset. Taking P value < 0.05 as the inclusion criterion, the common genes in all datasets were selected as prognostic genes, and a 9-gene prognostic signature was developed.Results The Kaplan-Meier survival curve was constructed using log-rank test to assess survival differences. The overall survival of patients in the low-risk group was significantly higher than that in the high-risk group. ROC analysis showed that this 9-gene signature showed good diagnostic efficiency both in overall survival(OS) and disease free survival(DFS). The 9-gene signature was further validated using GSE16446 dataset. In addition, multiple Cox regression analysis showed that this 9-gene signature was an independent risk factor. Finally, we established a nomogram that integrates conventional clinicopathological features and 9-gene signature. The analysis of the calibration plots showed that the nomogram has good performance.Conclusions This study has developed a reliable 9-gene prognostic signature, which is of great value in predicting the prognosis of BRCA and will help to make personalized treatment decisions for patients at different risk score.

  • Open Access

    Atypical ubiquitin-binding protein SHARPIN promotes breast cancer progression

    by Zelin Tian, Jianing Tang, Qian Yang, Xin Li, Jian Zhu, Gaosong Wu